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ABSTRACT
Aim: To investigate the dosimetric impacts of lung tumor motion in robotic hypofractionated radiotherapy for lung cancers 
delivered through continuous tracking of the vertebrae by the XSight Spine Tracking (XST) mode of the CyberKnife. 
Materials and Methods: Four‑dimensional computed tomography (4DCT) scans of a dynamic thorax phantom were acquired. 
Three motion patterns (one‑dimensional and three‑dimensional) of different range were investigated. Monte Carlo dose distributions 
were generated with 4DCT‑derived internal target volume (ITV) with a treatment‑specific setup margin for 12.6 Gy/3 fractions. 
Six‑dimensional error correction was performed by kV stereoscopic imaging of the phantom’s spine. Dosimetric effects of intrafractional 
tumor motion were assessed with Gafchromic films (Ashland Inc, Wayne, NJ, USA) according to 1) the percent measurement dose 
points having doses above the prescribed (P > Dpres), mean (P > Dm), and minimum (P > Dmin) ITV doses, and 2) the coefficient of variation (CV). 
Results: All plans attained the prescription dose after three fractions despite marked temporal dose variations. The value of P > Dpres 
was 100% after three fractions for all plans, but could be smaller (~96%) for one fraction. The values of P > Dmin and P > Dm varied 
drastically interfractionally (25%‑2%), and could be close to 0% after three fractions. The average CV ranged from 2.8% to 7.0%. 
Correlations with collimator size were significant for P > Dmin and P > Dm (P < 0.05) but not P > Dpres (P > 0.05). 
Conclusions: Treating lung tumors with CyberKnife through continuous tracking of the vertebrae should not be attempted without 
effective means to reduce the amplitude and variability of target motion because temporal dose variations owing to the intrafractional 
target motion can be significant.
KEYWORDS: CyberKnife, hypofractionated stereotactic lung radiotherapy, intrafractional organ motion, tracking
Original Article
INTRODUCTION
Recently, CyberKnife (Accuray Inc., Sunnyvale, 
CA, USA), a robotic‑based radiosurgical system, 
has been increasingly employed for stereotactic 
body radiotherapy (SBRT) of lung cancers.[1,2]
Unlike conventional linac‑based SBRT, CyberKnife 
mainly involves non‑isocentric and non‑coplanar 
irradiation by a large of small photon beams.
The CyberKnife offers two solutions for treating 
mobile lung tumors, either by Fiducial Tracking 
which requires radiopaque fiducial markers to 
be implanted in or near the tumor,[1] or by XSight 
Lung Tracking (XLT) which uses the tumor shape 
for tracking and is hence fiducial free.[3] Both 
target tracking methods could be combined with 
the Synchrony real‑time respiratory tracking 
system (RTS).[4] The technical basis of the RTS 
is a correlation model between an external 
breathing signal and internal target positions 
determined from stereoscopic x‑ray imaging of the 
implanted fiducials or the tumor combined with the 
compensation of that motion by the robotic arm.
The RTS is most suitable for strong moving tumors 
because the gain in safety margin reduction is 
proportional to the range of target motion. But 
for tumors that are attached to rigid structures 
such as the spinal column and chest wall and that 
exhibit a small range of motion, fiducial‑based RTS 
may become unjustified considering the additional 
risks of pneumothorax[5]and fiducial migration[6]. 
Furthermore, smaller intra‑and interfractional 
variability of the tumor baseline position was 
observed with smaller tumor‑to‑vertebrae 
distance.[7,8] The XLT method, on the other hand, 
is not applicable to all lung tumors as not all 
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tumors are visible on the x‑ray images due to size and 
location. Alternatively, the XSight Spine tracking (XST),[9] an 
offline setup correction strategy that is originally intended 
for tracking vertebral anatomy in SBRT for spine tumors, 
may be applied. Such treatment setup strategy coincides in 
concept with the recently available lung optimized treatment 
option, called 0‑view tracking mode, which utilizes the 
XST of adjacent vertebrae for global patient alignment. 
Compared to megavoltage (MV) electronic portal imaging 
device, kilovoltage (kV) stereoscopic imaging with the XST 
system offers superior image quality of bony anatomy for 
accurate auto‑registration with the digitally reconstructed 
radiographs (DRRs). Because XST is not capable of tumor 
motion tracking and does not account for the interfractional 
and intrafractional uncertainties of the tumor positions larger 
safety margin is needed compared to the real‑time correction 
by direct tumor detection.
Similar to non‑gated treatments, XST requires an internal target 
volume (ITV) to account for the effect of the semi‑periodic 
respiration induced organ motion. When a large number of 
small photon beams are combined to dose paint the tumor 
volume, it often assumes that the tumor moves within a 
spatially invariant dose cloud. Clearly, as the tumor moves 
in and out of the radiation fields following the respiratory 
motion, the delivered dose to each voxel of the tumor may 
not add up to its expected total dose. As shown in a landmark 
study by Bortfeld et al.,[10] the dose variance introduced by 
tumor motion depends on the delivery technique because of 
the arbitrary respiratory phase. The dosimetric impacts of 
the intrafractional target motion have been experimentally 
investigated in conventional linac‑based isocentric irradiation 
by Richter et al.[11] for single beam, by Nakamura et al. 
and Huang et al. for coplanar and noncoplanar conformal 
radiotherapy,[12,13] by Jiang et al.[14] for sliding and step‑and‑shot 
intensity‑modulated radiotherapy (IMRT), and Ong et al. for 
volumetric arc radiotherapy.[15] On the contrary, our group has 
performed experimental investigations of the intrafractional 
target motion for the CyberKnife focusing on the RTS.[16,17] While 
it is hypothesized that XST based lung tumor treatment may be 
beneficial for a subset of patients who are medically inoperable, 
unsuitable for invasive fiducial implantation and whose tumors 
are not visible on the x‑ray tracking system or attached to the 
vertebral column with limited motion range, experimental 
evaluations of this delivery technique have never been reported 
despite its increasing clinical applications.[18‑20] In this study, we 
aimed to evaluate the adequacy of using the XLS‑based strategy 
by studying the dose delivered to a moving tumor. Experimental 
measurements were made with Gafchromic films placed inside 
a thorax phantom with a moving tumor substitute.
MATERIALS AND METHODS
Motion phantom setup
The dynamic thorax phantom (CIRS Inc., Norfolk, VA, USA) used 
in this experimental study consisted of a moving spherical 
target with film inserts that can accommodate Gafchromic 
films (Ashland Inc., Wayne, NJ, USA) in coronal and axial planes. 
For our study we used EBT2 film. The tumor substitute has a 
density of 1.06 g/cc and was embedded in the center of the 
spherical target. The phantom was programmed to move the 
target in a fixed period of 4s and at variable amplitudes: #1) 
10mm in the superior‑inferior (SI) direction, #2) 20 mm in the SI, 
5 mm in the anterior‑posterior (AP), and 2 mm in the lateral (LR) 
direction, and #3) 10 mm in the SI, 5 mm in the AP, and 2 mm in 
the LR direction. The motion parameters were chosen according 
to the analysis of our institution that most tumors exhibited 
motion principally in the SI direction (mean = 8 mm) and less 
in the AP direction (3 mm) and the LR direction (1 mm). A large 
motion range of 20 mm was also included as an extreme 
scenario. The maximum distance between the target’s center 
and the phantom’s spine was 6.5 cm. Constant motion was 
assumed in four‑dimensional computed tomography (4DCT) 
simulation and treatment deliveries.
4DCT simulation, target definition and ITV‑to‑PTV margin 
determination
4DCT images of 1.25mm thickness were acquired on a GE 
Light Speed 64‑slice computed tomography scanner (General 
Electric Company, Waukesha, WI, USA) together with the 
real‑time position management system (RMP, Varian Medical 
Systems, Palo Alto, CA, USA). The 4DCT dataset was then sent 
to the Advantage Workstation (General Electric Company, 
Waukesha, WI, USA) for post‑processing using the Advantage 
4DCT software. For each 4DCT dataset, 10 equally time‑binned 
three‑dimensional computed tomography (3DCT) datasets 
were created, with the 0% image dataset and the 50% image 
dataset roughly corresponding to the end‑inhale phase and 
end‑exhale phase in the respiratory cycle. Additionally, we 
created two reconstructed datasets using maximum‑intensity 
projection (MIP) and average‑intensity projection (AVG). The 
MIP and AVG created 3DCT images that represented the 
greatest and average voxel intensity values throughout the 
4DCT dataset, respectively.
Both the MIP and the AVG datasets were imported into the 
Multiplan v. 4.0.x (Accuray Inc., Sunnyvale, CA, USA) treatment 
planning system (TPS). The ITV was produced as the union 
of the simulated gross tumor volume (GTV) over the motion 
trajectory on the MIP images. Margins from the ITV to the 
planning target volume (PTV) were calculated according to 
the Wolthaus et al.[21]’s margin recipe based on the published 
data of inter‑ and intrafractional variability of tumor baseline 
shift.[7,8] The resulting total margins were 15.0‑20.5 mm for the 
SI direction, 4.5‑5.5 mm for the LR direction, and 7.5‑10.0 mm 
for the AP direction.
Treatment planning and treatment setup
Multiplan (v. 4.0.x) was also used for treatment planning. 
The tracking method to be used for treatment correction was 
defined prior to plan optimization and dose calculation, in 
which case we used the XST mode.[22] In the XST mode, a region 
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of interest (ROI) that included a spine volume extending two 
vertebrae beyond the full PTV’s length was defined. For each 
motion profile, we performed Monte Carlo dose optimization 
on the AVG images using two different collimators, one with 
a dimension comparable to the PTV’s long axis and the other 
of a dimension that just matched the planning GTV (15 mm). 
For motion pattern #1, 20 and 35 mm circular collimators 
were chosen for treatment planning. For motion pattern #2, 
20 and 40 mm collimators were used. For motion pattern #3, 
20 and 35 mm collimators were chosen. In addition to the 
calculated ITV‑to‑PTV margins, we created two other plans 
with a fixed 5 mm ITV‑to‑PTV margin for a given motion 
profile (motion #3). This aimed to assess the sensitivity of 
dose received by the GTV to the ITV‑to‑PTV size. Therefore, a 
total of four treatment plans using 12.5, 20, 25, and 35 mm 
were created for motion #3. The Monte Carlo dose calculation 
algorithm of the MultiPlan TPS has been previously described 
by Ma et al.[23], and basically implements the MCDOSE, an EGS4 
user code. All Monte Carlo dose calculations were performed 
at 0.5%‑1% relative statistical uncertainty. The dose grid 
resolution was approximately 1.47 × 1.47 × 1.25 mm. Dose 
distributions were Gaussian‑smoothed to reduce statistical 
noise. Total doses of 12.6 Gy in 3 fractions were prescribed 
to 65%‑73% isodose lines (maximum dose = 100%) to 
achieve > 99% target coverage. Table 1 gives a summary of 
the final treatment plans. The fractioned dose was scaled to 
4.2 Gy in order to accommodate the dose range applicable to 
the red channel of the Gafchromic EBT2 films.
Treatment setup was performed with the XST. Briefly, when 
the phantom loaded with the EBT2 films was placed on 
the treatment couch, stereoscopic kV image pairs were 
acquired and compared with synthetic DRRs computed 
a different angles in the predefined ROI of the spine 
Figure 1: XSight Spine tracking registered the bony spine anatomy between the digitally reconstructed radiographs and the corresponding orthogonal 
stereoscopic images. The registration results, which are circled on the right, are three translational (left-right, superior-inferior and anterior-posterior) 
and three rotational errors (yaw, tilt, and roll). The shadow of the target appeared above (upper row) and beneath (bottom row) the spine structure
Table 1: Summary of the treatment plans with listed values 
of minimum dose (Dmin), mean dose (Dmean), and maximum 
dose (Dmax) to the internal target volume
Motion Collimator 
(mm)
Dmin 
(Gy)
Dmean 
(Gy)
Dmax 
(Gy)
HI
Motion #1 (10 mm in SI) 20 5.7 6.2 6.5 1.54
35 5.0 5.4 6.0 1.43
Motion #2 (20 mm in SI, 
5mm in AP, 2 mm in LR)
20  4.5 5.3 6.0 1.43
40 5.4 5.7 6.0 1.43
Motion #3 (10 mm in SI, 
5 mm in AP, 2 mm in LR)
20 4.8 5.5 6.0 1.43
35 5.0 5.4 5.8 1.37
12.5 4.3 5.3 6.1 1.47
25 5.0 5.6 6.0 1.43
HI=Homogeneity index, LR=Left-right, SI=Superior-inferior
structure by intensity‑based 2D‑3D registration [Figure 1].[9] 
The registration resulted in three translational and three 
rotational errors given as the differences of the spine structure 
between the treatment position and the planned position. 
These errors were subsequently corrected by movement of 
the treatment couch until the setup errors were reduced to 
less than 0.5 mm (translational) and 0.5° (rotational). The 
residual error for the spine alignment was then corrected by 
the CyberKnife robot and the treatment beams were delivered 
to the moving target according the spine‑tumor relation from 
the planning CT.
We used an Epson Expression 1680 flatbed scanner (Seiko 
Epson Corporation, Nagano, Japan) to scan the exposed 
EBT2 films after post exposure ageing of 24 hours with 
the following settings: (1) transmission mode, (2) 48 bit 
color (RGB), (3) resolution of 150 dpi (0.017 cm/pixel), (4) 
no color correction, and (5) portrait orientation. EBT2 films 
were calibrated against measurements with an ion‑chamber. 
The red‑channel images of the EBT2 films were registered 
by the use of the Image Processing Toolbox™ of Matlab 
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(The MathWork, Inc., Natick, MA, USA). We used an in‑house 
Matlab program to analyze the dose distributions.
Dosimetric evaluations
Measured dose distributions were analyzed based on the 
percentage dose point that received a dose larger than the 
calculated prescription dose, minimum dose, and mean dose, 
denoted as P 
> Dpres
, P 
> Dmin
, and P 
> Dmean
, respectively. We used 
the coefficient of variation (CV) to evaluate the temporal dose 
variation. It is defined as
CV
d
= ×
σ
100%, (1)
where σ is the standard deviation and d is the average dose 
in a single pixel over three fractions. A smaller CV indicated 
smaller dose variation in each pixel.
RESULTS
Figure 2 presents the cumulative dose distributions measured 
in the axial and coronal planes cutting through the GTV’s 
center. Except the dose distribution obtained with the smallest 
12.5 mm collimator, Figure 2 shows that all other measured 
dose distributions (in cGy) decreased from inside out, a pattern 
characteristic of the heterogeneous dose distribution with 
Figure 2: Cumulative dose distributions in the axial and coronal planes through the center of the gross tumor volume for different motion patterns 
and collimators. Doses are in cGy (see color bar)
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larger collimators in SBRT. The cumulative dose distribution of 
the 12.5 mm collimator showed a reversed pattern in which 
the dose distribution was colder at the center characteristic of 
dose distributions for the CyberKnife with small collimators. 
More importantly, it demonstrates that the target attained the 
prescription dose of 12.6 Gy after the same plan was delivered 
three times, provided that the motion pattern remained 
constant from planning to delivery. Figure 3 illustrated 
the distributions of measured dose variations (1 SD) over three 
fractions in the axial and coronal films. Qualitatively, the dose 
variations tended to be greater in the coronal films than in the 
axial films. The dose variations were largest in the plan using 
25 mm collimator for motion #3 and were smallest in the plan 
using 40 mm collimator for motion #2. In general, the dose 
variations differed from plan to plan without a clear pattern of 
correspondence to the composite dose distributions in Figure 2.
Figure 3: Distributions of the measured dose variations (1 standard deviation) in the coronal and axial planes of the moving target after the same 
treatment plans were delivered three times. Dose variations are in cGy (see color bar)
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Table 2: Percent dose points that have measured dose 
values larger than the prescription dose (P>Dpres), mean 
dose (P>Dmean), and minimum dose (P>Dmin) were calculated 
for each fraction and were averaged over three fractions. 
Also, given are the coefficients of variation
Motion Fraction no. P>Dpres P>Dmin P>Dmean CV 
Motion #1
20 mm collimator 1 100.0 85.0 0.0
2 100.0 77.2 1.7
3 100.0 71.1 9.6
Cumulative 100.0 89.1 0.0 3.7
35 mm collimator 1 100.0 72.6 7.8
2 100.0 40.3 0.0
3 100.0 73.8 7.6
Cumulative 100.0 62.7 0.0 3.2
Motion #2
20 mm collimator 1 100.0 99.2 0.0
2 100.0 100.0 34.1
3 100.0 100.0 13.1
Cumulative 100.0 100.0 3.5 4.6
40 mm collimator 1 100.0 25.5 1.1
2 100.0 1.9 0.0
3 100.0 1.7 0.0
Cumulative 100.0 0.0 0.0 2.8
Motion #3
20 mm collimator 1 98.4 53.5 0.1
2 100.0 67.1 6.5
3 100.0 80. 5 22.6
Cumulative 100.0 67.7 4.6 3.8
35 mm collimator 1 100.0 100.0 0.1
2 100.0 99.7 0.0
3 100.0 63.1 0.0
Cumulative 100.0 99.4 0.0 3.8
12.5 mm 
collimator
1 97.4 94.8 24.6
2 97.8 94.7 9.4
3 100.0 99.5 31.0
Cumulative 100.0 99.0 20.1 4.0
25 mm collimator 1 96.5 12.0 0.0
2 100.0 95.7 25.7
3 100.0 85.9 6.8
Cumulative 100.0 80.9 0.1 7.0
CV=Coefficient of variation
Figure 4: Coefficient of variation histograms for all motion patterns with 
different collimator sizes. Average coefficient of variation values are 
given on the histograms as “ave. coefficient of variation”
For quantitative analysis, we calculated the percentage 
of dose points exceeding the prescribed dose (P
 > Dpres
), the 
calculated minimum dose (P
 > Dmin
), and the calculated mean 
dose (P
 > Dmean
) as a function of the motion pattern [Table 2]. 
Table 2 shows that P 
> Dpres
 was < 100% for only a few single 
fractions, but the cumulative P 
> Dpres
 approached 100% in 
all treatments. In contrast, the values of P 
> Dmin
 and P 
> Dmean 
were seen to differ significantly between fractions. For 
example, P 
> Dmin 
can vary from ~ 25% in the first fraction 
to ~ 2% in the remaining fractions and ends up ~ 0% after 
three fractions. The cumulative P 
> Dmin
 ranged from 0% to 
99.4% (74.9 ± 33.5% [mean ± 1 standard deviation]). The 
cumulative P 
> Dmean
 were <5% except for the plans using the 
12.5 mm collimator. Figure 4 showed the histograms of the 
CV for each motion profile. The average CV for all dose points 
is shown in the CV histograms for different collimators. For 
motion #1, the CV ranged from 0.02% to 7.53%, whereas for 
motion #2, the CV ranged from 0.03% to 8.90%, and last, 
for motion #3, the CV ranged from 0.01% to 11.80% for a 
normal ITV‑to‑PTV margin and from 0.59% to 11.85% for a 
reduced margin.
Results of the Mann‑Whitney U tests showed that P 
> Dpres
, P 
> Dmean
, 
and P 
> Dmin
 were insensitive to the margin size (P > 0.05), at 
least for a 3D translational motion of clinically relevant 
amplitude (e.g., SI = 10mm, AP = 5mm, and LR = 2mm). 
The Spearman’s rank correlation coefficients between 
P 
> Dpres
, P 
> Dmean
, and P 
> Dmin
 and collimator size were r = 0.39, 
‑0.56, and ‑ 0.49, respectively. The correlation coefficients 
were significant for P 
> Dmean
 and P 
> Dmin
 (P < 0.05) but not 
P 
> Dpres 
(P >
 
0.05).
DISCUSSION
In this study, we investigated the feasibility of highly 
conformal stereotactic body radiation therapy (SBRT) by using 
CyberKnife for lung tumors that are attached to the rigid spine 
structure and exhibit small motion. This strategy adapted the 
XSight Spine Tracking system (XST) for setup correction and 
employed individualized internal target volumes (ITV) with an 
additional margin for inter‑ and intrafractional variability of 
the tumor baseline. The dosimetric impact of such treatment 
strategy for SBRT was evaluated with Gafchromic EBT2 films 
in a lung phantom consisting of a moving target and a static 
spine structure. Assuming constant target motion during 
4DCT scanning and delivery, our results showed that the 
gross target volume (GTV) received the prescription dose after 
three fractions despite a marked temporal dose variation. 
No serious impact of tumor control probability is expected 
because the cumulative P 
> Dpres
 was 100% for all plans, even 
though it can be smaller (~96%) in a single fraction. On the 
contrary, values of P 
> Dmean 
for each fraction and after three 
fractions were < 5% for all plans except one, suggesting 
that the overall effect of target motion was decreasing the 
delivered dose [Figure 3]. In practice, values of P 
> Dpres
, P 
> Dmean
, 
and P 
> Dmin
 primarily depended on the planned dose to the ITV 
and did not differ by margin size, because with only periodic 
motion the idealized 5 mm margin was enough to compensate 
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for the dose blurring at the planning target volumes (PTV) 
edge. Nonetheless, strong temporal dose variations were 
evidenced in the histogram plots of the CV [Figure 4]. The 
average CV was ~ 3.5% for small motion (10 mm SI motion) 
and up to 7.0% for large SI motion (20 mm) with a reduced 
5 mm ITV‑to‑PTV margin. In an experimental study, Jiang 
et al.,[14]found negligible dose variation of 1%‑2% in a chamber 
measurement that was made in a moving phantom after 30 
fractions, independent of the MLC delivery mode. In the other 
study, Ehler et al.[24] found a CV of 1.14%‑5.51% in segment 
IMRT and 3.83%‑8.25% in dynamic IMRT in measurements that 
were made with a moving detector array. Due to variations 
of phantom setup (e.g. homogeneous vs. heterogeneous 
phantom), dose calculation algorithms (e.g. Monte Carlo vs. 
pencil beam) and fractionation schemes, direct comparisons 
between the results of these studies are difficult. In our case, 
the increased dose variations can be explained by the large 
dose gradients (e.g. 27%~35%) inside the PTV. This was in 
contrast to conventional 3D conformal radiotherapy and IMRT, 
where the effect of target motion is generally pronounced at 
the field edge, but negligible at the center of the uniform field.
In SBRT, fractioned doses are up to 15‑20 Gy, ‑3‑4.5 times 
that of this study. If we were to deliver 20 Gy, the dose per 
fraction and hence the number of monitor units per beam 
would be roughly scaled up 4.5 times accordingly. This may 
have some impact on the resulting dose because the larger 
the number of monitor units (i.e., longer treatment time), the 
higher the probability of the target will be sampled by the 
treatment beams. The reduced dose error with larger number 
of monitor units has been recently examined by Ong et al.[25] in 
multileaf collimator‑based hypofractionated stereotactic lung 
radiotherapy. Because issues with MLC may not be strictly 
relevant to the robotic‑based IMRT, more studies are necessary 
for understanding how these factors influence the delivered 
dose in the present robotic‑based treatment scenario.
One of the limitations of this study is the relatively large 
target‑to‑spine distance in the phantom as this technique is 
aimed for tumors in the immediate vicinity of the spinal column. 
However, we do not expect that the results would be affected 
by the target‑to‑spine distance because of the constant and 
regular target motion and the overall rigidness of the phantom. 
Nevertheless, intrafractional and interfractional variability of 
tumor motion range, period and baseline are noted frequently 
in lung radiotherapy.[7,26] Although we explicitly calculated the 
extra setup margins for these uncertainties, we were unable to 
assess their dosimetric effects with the present experimental 
setup. It is expected that increased inter‑ and intrafractional 
tumor baseline drifts relative to the tracking spine volume 
may increase the delivered dose errors. Huang et al.[13] recently 
showed that treatment plans created with inaccurate ITV 
led to underdosing (10%) in a portion of the PTV when the 
irregular target motion was large (~20 mm), whereas good 
agreement between planned and measured dose distributions 
was observed for irregular motion <8.8 mm. This seemed 
to be consistent with our preliminary results that measured 
minimum and mean doses tended to decrease with increasing 
motion amplitude (10 mm vs. 20 mm).
Because XST represents an offline treatment setup strategy, 
it is impossible to reduce the setup margin. Yet, there is great 
potential to reduce the internal margin despite non‑real‑time 
tracking. Murphy et al.[27] have demonstrated the effectiveness 
of breath‑holding to reduce and stabilize the tumor motion 
in hypofractionated radiotherapy. A major concern of such 
breath‑held approach is prolonging the treatment duration 
beyond the patient’s compliance. Recently, the concept of 
time‑weighted average tumor position has been proposed 
by Wolthaus et al.[21] Unlike the concept of ITV which aims to 
provide 100% dose coverage to the clinical target volume (CTV) 
during the entire breathing cycle, Wolthaus et al.[21] suggested 
that, if a treatment plan is designed for the tumor at its 
time‑weighted average position during the breathing cycle, 
a good dose coverage is still obtained even though the target 
is not fully within the PTV during a short portion of the 
breathing cycle. Guckenberger et al.[28] estimated that 2.4 and 
6 mm margins around the CTV at the time‑weighted average 
position were needed to compensate for motion amplitudes 
of 10 and 20 mm. This nearly halves the internal margin. If 
such margin design is adapted to treatment planning of our 
proposed strategy, it may be possible to reduce the total safety 
margin from 15.2 to 11.9 mm and 20.7 to 15.1 mm for motion 
amplitudes of 10 and 20 mm. In addition, stereoscopic images 
do not provide volumetric information about changes in tumor 
volume that has been noted by Britton et al.[29] It is important to 
repeat 4DCT simulation to confirm that there is no continuous 
progressive change in tumor volume and position, particularly 
for hypofractionated/accelerated regimens that take a few 
weeks to complete.
CONCLUSIONS
For the first time, a quantitative dosimetric evaluation of 
target motion in robotic hypofractionated delivered using the 
XSight Spine Tracking method was performed. Although the 
target received the prescription dose after three fractions, this 
technique should be used with caution because the temporal 
dose variations can be significant. Unless effective means 
are employed to reduce the safety margin and variability of 
tumor motion, we do not recommend the non‑real‑time spine 
tracking strategy for treating tumors with motion of more 
than 10 mm. Finally only long term clinical evaluation of this 
method will demonstrate efficacy of this treatment strategy.
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